Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease

被引:129
|
作者
Buchheit, Kathleen M. [1 ,3 ]
Cahill, Katherine N. [1 ,3 ]
Katz, Howard R. [1 ,3 ]
Murphy, Katherine C. [3 ]
Feng, Chunli [3 ]
Lee-Sarwar, Kathleen [1 ]
Lai, Juying [3 ]
Bhattacharyya, Neil [2 ,4 ]
Israel, Elliot [1 ,5 ]
Boyce, Joshua A. [1 ,3 ]
Laidlaw, Tanya M. [1 ,3 ]
机构
[1] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[2] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Otolaryngol, 75 Francis St, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Pulm Med, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
Aspirin-exacerbated respiratory disease; Samter triad; nasal polyps; thymic stromal lymphopoietin; prostaglandin D-2; cysteinyl leukotrienes; innate immunity; mast cells; eosinophils; INNATE LYMPHOID-CELLS; HUMAN EPITHELIAL-CELLS; MAST-CELL; EOSINOPHILIC INFLAMMATION; CYSTEINYL LEUKOTRIENES; CHRONIC RHINOSINUSITIS; ALLERGIC INFLAMMATION; CYTOKINE PRODUCTION; ASTHMATIC AIRWAYS; EXPRESSION;
D O I
10.1016/j.jaci.2015.10.020
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Prostaglandin (PG) D-2 is the dominant COX product of mast cells and is an effector of aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease (AERD). Objective: We evaluated the role of the innate cytokine thymic stromal lymphopoietin (TSLP) acting on mast cells to generate PGD(2) and facilitate tissue eosinophilia and nasal polyposis in patients with AERD. Methods: Urinary eicosanoid levels were measured in aspirin-tolerant control subjects and patients with AERD. Nasal polyp specimens from patients with AERD and chronic rhinosinusitis were analyzed by using quantitative PCR, Western blotting, and immunohistochemistry. Human cord blood-and peripheral blood-derived mast cells were stimulated with TSLP in vitro to assess PGD(2) generation. Results: Urinary levels of a stable PGD(2) metabolite (uPGD-M) were 2-fold higher in patients with AERD relative to those in control subjects and increased further during aspirin-induced reactions. Peak uPGD-Mlevels during aspirin reactions correlated with reductions in blood eosinophil counts and lung function and increases in nasal congestion. Mast cells sorted from nasal polyps expressed PGD(2) synthase (hematopoietic PGD(2) synthase) mRNA at higher levels than did eosinophils from the same tissue. Whole nasal polyp TSLP mRNA expression correlated strongly with mRNA encoding hematopoietic PGD(2) synthase (r = .75), the mast cell-specific marker carboxypeptidase A3 (r = .74), and uPGD-M (r=0.74). Levels of the cleaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those in aspirin-tolerant control subjects. Recombinant TSLP induced PGD(2) generation by cultured human mast cells. Conclusions: Our study demonstrates that mast cell-derived PGD(2) is a major effector of type 2 immune responses driven by TSLP and suggests that dysregulation of this innate system contributes significantly to the pathophysiology of AERD.
引用
收藏
页码:1566 / +
页数:16
相关论文
共 50 条
  • [41] Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease
    Stevenson, DD
    Mehra, PK
    White, AA
    Gupta, S
    Woessner, KM
    Simon, RA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 116 (04) : 755 - 760
  • [42] Eosinophil Production of PGD2 in Aspirin-Exacerbated Respiratory Disease
    Steinke, John W.
    Negri, Julie
    Baker, Mary Grace
    Payne, Spencer
    Borish, Larry
    Feng, Xin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB187 - AB187
  • [43] Cortactin expression in nasal polyps of Aspirin-Exacerbated Respiratory Disease (AERD) patients
    Brescia, Giuseppe
    Parrino, Daniela
    Nicole, Lorenzo
    Zanotti, Claudia
    Lanza, Cristiano
    Barion, Umberto
    Marino, Filippo
    Marioni, Gino
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2018, 39 (03) : 293 - 298
  • [44] What Is the Next Step for Patients With Aspirin-Exacerbated Respiratory Disease: Biologics With or Without Aspirin Therapy?
    Szatkowski, Piotr
    Mastalerz, Lucyna
    ALLERGY, 2024,
  • [45] Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease
    Brown, Alyson N.
    Laidlaw, Tanya M.
    Buchheit, Kathleen M.
    Bensko, Jillian C.
    Corcoran, Rose C.
    Bailey, Laura B.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (06): : 1647 - 1648
  • [46] SERUM IL-6 LEVELS IN PATIENTS WITH ASPIRIN-EXACERBATED RESPIRATORY DISEASE
    Kapil, A.
    Moore, D.
    Bernstein, J.
    Mahdavinia, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S12 - S12
  • [47] FACTORS ASSOCIATED WITH UNCONTROLLED SEVERE ASTHMA IN PATIENTS WITH ASPIRIN-EXACERBATED RESPIRATORY DISEASE
    Mitsui, Chihiro
    Taniguchi, Masami
    Fukutomi, Yuma
    Ono, Emiko
    Higashi, Noritaka
    Mita, Haruhisa
    Akiyama, Kazuo
    RESPIROLOGY, 2013, 18 : 13 - 13
  • [48] Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease
    Woessner, KM
    Simon, RA
    Stevenson, DD
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2004, 93 (04) : 339 - 344
  • [49] Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease
    Berges-Gimeno, MP
    Simon, RA
    Stevenson, DD
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) : 180 - 186
  • [50] Induced sputum periostin decreases during aspirin desensitization in aspirin-exacerbated respiratory disease patients
    Tyrak, K. E.
    Kuprys-Lipinska, I
    Cmiel, A.
    Plutecka, H.
    Gielicz, A.
    Gawronska, A.
    Krzyzanowski, D.
    Koziej, M.
    Zal, A.
    Sanak, M.
    Strek, P.
    Kuna, P.
    Mastalerz, L.
    ALLERGY, 2018, 73 : 199 - 199